Clinical Trial

A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 15, 2026 (before its estimated May 29, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2022-11-21; most recent amendment 2026-05-12.
Status change: Recruiting → Active, Not Recruiting 2025-08-22
Status change: Not Yet Recruiting → Recruiting 2023-01-03
Trial Details
NCT Number NCT05633459
Lead Sponsor QurAlis Corporation
Conditions Amyotrophic Lateral Sclerosis
Enrollment 69 participants
Start Date 2022-12-16
Primary Completion 2026-05-29 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-15